Alemtuzumab use in relapsed and refractory chronic lymphocytic lymphoma.

Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

Volumn 2011, Issue , 2011, Pages 119-120

  Arnason, Jon E ^a   Brown, Jennifer R ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; MONOCLONAL ANTIBODY;

ARTICLE; CASE REPORT; CHROMOSOME 17; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; MIDDLE AGED; RECURRENT DISEASE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 84859399749     PISSN: None     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2011.1.119     Document Type: Article

References (0)